264 related articles for article (PubMed ID: 24141721)
1. miR-661 downregulates both Mdm2 and Mdm4 to activate p53.
Hoffman Y; Bublik DR; Pilpel Y; Oren M
Cell Death Differ; 2014 Feb; 21(2):302-9. PubMed ID: 24141721
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
Swetzig WM; Wang J; Das GM
Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
[TBL] [Abstract][Full Text] [Related]
3. microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network.
Hoffman Y; Pilpel Y; Oren M
J Mol Cell Biol; 2014 Jun; 6(3):192-7. PubMed ID: 24868102
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame.
Mandke P; Wyatt N; Fraser J; Bates B; Berberich SJ; Markey MP
PLoS One; 2012; 7(8):e42034. PubMed ID: 22870278
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
6. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
7. S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
Liu L; Fan L; Fang C; Zou ZJ; Yang S; Zhang LN; Li JY; Xu W
Cancer Sci; 2012 Dec; 103(12):2056-63. PubMed ID: 22937789
[TBL] [Abstract][Full Text] [Related]
8. TP53/miR-129/MDM2/4/TP53 feedback loop modulates cell proliferation and apoptosis in retinoblastoma.
Yao X; Shen H; Peng Q; Yu J
Cell Cycle; 2021; 20(5-6):603-615. PubMed ID: 33678118
[TBL] [Abstract][Full Text] [Related]
9. CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
Štětková M; Growková K; Fojtík P; Valčíková B; Palušová V; Verlande A; Jorda R; Kryštof V; Hejret V; Alexiou P; Rotrekl V; Uldrijan S
Cell Death Dis; 2020 Sep; 11(9):754. PubMed ID: 32934219
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450
[TBL] [Abstract][Full Text] [Related]
11. Mouse double minute homologue 2 (MDM2) downregulation by miR-661 impairs human endometrial epithelial cell adhesive capacity.
Winship A; Ton A; Van Sinderen M; Menkhorst E; Rainczuk K; Griffiths M; Cuman C; Dimitriadis E
Reprod Fertil Dev; 2018 Mar; 30(3):477-486. PubMed ID: 28847363
[TBL] [Abstract][Full Text] [Related]
12. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.
Prodosmo A; Giglio S; Moretti S; Mancini F; Barbi F; Avenia N; Di Conza G; Schünemann HJ; Pistola L; Ludovini V; Sacchi A; Pontecorvi A; Puxeddu E; Moretti F
J Mol Med (Berl); 2008 May; 86(5):585-96. PubMed ID: 18335186
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4.
Fan C; Wang X
Cell Cycle; 2017 Apr; 16(7):660-664. PubMed ID: 28166445
[TBL] [Abstract][Full Text] [Related]
14. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
15. MDM4 is a key therapeutic target in cutaneous melanoma.
Gembarska A; Luciani F; Fedele C; Russell EA; Dewaele M; Villar S; Zwolinska A; Haupt S; de Lange J; Yip D; Goydos J; Haigh JJ; Haupt Y; Larue L; Jochemsen A; Shi H; Moriceau G; Lo RS; Ghanem G; Shackleton M; Bernal F; Marine JC
Nat Med; 2012 Aug; 18(8):1239-47. PubMed ID: 22820643
[TBL] [Abstract][Full Text] [Related]
16. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
17. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
18. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA Control of p53.
Liu J; Zhang C; Zhao Y; Feng Z
J Cell Biochem; 2017 Jan; 118(1):7-14. PubMed ID: 27216701
[TBL] [Abstract][Full Text] [Related]
20. miR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2.
Jansson MD; Damas ND; Lees M; Jacobsen A; Lund AH
Oncogene; 2015 Apr; 34(15):1908-18. PubMed ID: 24882579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
